Adaptogenic Botanicals in Dermatological Regeneration

Abstract

Plasma skin regeneration (PSR) and low-temperature plasma (LTP) technologies have demonstrated clinically significant improvements in facial rhytids, dyspigmentation, skin elasticity, and scar remodelling. Independently, adaptogenic and medicinal botanicals — including Centella asiatica, Curcuma longa, Epimedium brevicornum, Nigella sativa, and Camellia sinensis — possess well-characterised anti-inflammatory, collagen-stimulating, antioxidant, and antimicrobial properties relevant to skin regeneration. Despite mechanistic complementarity, no published studies combine these two modalities.

This paper analyses the synergies between plasma-based dermatological procedures and topical botanical serum formulation, identifies eight critical research gaps, and proposes a framework for translational investigation. We argue that the post-plasma healing window (4–90 days) represents an underexploited therapeutic opportunity where bioactive botanical compounds could sustain and amplify the regenerative cascade initiated by plasma energy — particularly in collagen quality, microbiome recovery, and post-inflammatory hyperpigmentation prevention.

1. Background & Rationale

The dermatological application of adaptogenic botanicals has historically been limited to two domains: traditional topical preparations (Ayurvedic lepa, TCM external washes) and modern cosmeceutical formulations. In both cases, the botanical is applied to intact skin and must penetrate the stratum corneum — a significant barrier that limits the bioavailability of many high-molecular-weight phytochemicals (polysaccharides, glycosylated flavonoids, saponins).

Simultaneously, energy-based dermatological devices — lasers, radiofrequency, and plasma — have evolved toward controlled thermal injury protocols that trigger endogenous wound healing cascades (neocollagenesis, elastin remodelling, melanin redistribution). These procedures create a transient window of enhanced skin permeability and active cellular regeneration.

The convergence of these two fields — botanical pharmacology and energy-based dermatology — has not been systematically investigated. Post-procedure care universally defaults to bland emollients (petrolatum, aquaphor) that provide occlusion but no bioactive molecular support. This paper examines whether evidence-based botanical formulations, designed using the kask Serum Maker platform, could augment plasma skin regeneration outcomes.

2. Source Literature

3. Plasma Skin Regeneration — Mechanisms of Action

Plasma skin regeneration delivers energy to the skin through ionised nitrogen gas pulses. Unlike ablative lasers, PSR does not vaporise tissue — it transfers thermal energy to the skin surface in a controlled, uniform manner while the nitrogen purge eliminates oxygen, preventing charring and unpredictable hot spots [1]. The key mechanistic features are:

3.1 Thermal cascade without ablation

At low energy (1–2 J), thermal injury is limited to the epidermis and dermoepidermal junction. At high energy (3–4 J), thermal injury reaches the papillary dermis (8–12 μm) [1,2]. Critically, the desiccated epidermis remains intact as a natural biologic dressing, promoting reepithelialization underneath — complete by day 4–7 in the Bogle protocol [1].

3.2 Neocollagenesis

Histological analysis at 90 days post-treatment reveals a band of new collagen at the dermoepidermal junction (mean depth 72.3 μm) with reduced solar elastosis and interdigitating new collagen replacing dense elastin in the upper dermis [1]. This remodelling is progressive — Kilmer et al. reported continued improvement at 9 months [3].

3.3 Growth factor activation

Plasma energy stimulates endothelial cells to produce and secrete FGF-2 (fibroblast growth factor-2), VEGF (vascular endothelial growth factor), and nitric oxide, which coordinate cell proliferation and angiogenesis [2,4]. This growth factor release is the upstream trigger for the wound healing cascade that produces neocollagenesis.

3.4 Chromophore independence

Unlike laser-based systems, PSR does not rely on skin chromophores (melanin, haemoglobin, water) for energy absorption. This makes it applicable across all Fitzpatrick skin types — validated by Kongpanichakul et al. in Fitzpatrick III–V Asian skin [2] and by Almohammad et al. in Fitzpatrick III–IV Middle Eastern skin [5].

4. Botanical Compounds — Dermatological Mechanisms

The kask adaptogen database contains 46 species with 176 compounds, of which a significant subset has documented dermatological relevance. The following table summarises the key botanical actives and their mechanisms pertinent to skin regeneration:

5. Synergy Analysis

5.1 Complementary wound healing cascades — plasma primes, botanicals sustain

Plasma energy triggers an acute wound healing cascade: FGF-2 release, VEGF secretion, fibroblast activation, and neocollagenesis. Bogle demonstrated 72.3 μm of new collagen at 90 days [1]; Kongpanichakul showed elasticity R2 improvement from 0.70 to 0.86 [2]. This is a time-limited stimulus — the thermal injury heals within 4–7 days, and the collagen remodelling window extends approximately 3–12 months.

Botanical compounds can extend and amplify this window through convergent molecular targets:

• Centella asiatica asiaticoside directly stimulates type I/III collagen synthesis via TGF-β and BMP pathways — the same downstream targets that plasma activates upstream through thermal fibroblast stimulation.
• Curcuma longa curcumin inhibits NF-κB-driven inflammation that, if unchecked, converts productive wound healing into fibrosis and scarring — a critical modulator of healing quality.
• Epimedium brevicornum icariin promotes osteoblast differentiation via BMP-2/Smad4 — the same Smad signalling pathway involved in dermal fibroblast collagen production. Additionally, icariin's PDE5 inhibition enhances local microcirculation via NO/cGMP, potentially improving nutrient delivery to the regenerating dermis.

5.2 Melanin and pigmentation — convergent depigmentation

Kongpanichakul demonstrated significant melanin index reduction (250 → 207 periorbital, p<0.001) with LTP [2]. The Serum Maker includes several botanicals with independent depigmenting mechanisms operating at different points in the melanogenesis pathway:

• Glycyrrhiza glabra glabridin — inhibits tyrosinase, the rate-limiting enzyme in melanin biosynthesis
• Phyllanthus emblica ellagitannins — reduce oxidative stress-driven melanocyte activation (upstream of tyrosinase)
• Curcuma longa curcumin — inhibits melanocyte-stimulating hormone (MSH) signalling and suppresses melanosome transfer to keratinocytes

The combined protocol creates a sequential depigmentation strategy: plasma disrupts existing melanin deposits through thermal effect on melanosomes; botanical serum prevents re-accumulation via tyrosinase inhibition and antioxidant protection during the reepithelialization window. This is particularly relevant for Fitzpatrick III–V skin, where Kongpanichakul reported transient hyperpigmentation in 7.5% of subjects [2] — a complication that anti-inflammatory and depigmenting botanicals could mitigate.

5.3 Scar remodelling augmentation

Almohammad et al. demonstrated that single-pass high-energy PSR improves chronic cleft lip scar thickness (↓51.7%), relief (↓50.3%), and pliability (↓46.3%) [5]. Pliability showed the weakest improvement — suggesting that collagen reorganisation was less complete than collagen volume reduction.

Post-PSR botanical application could specifically target this pliability gap:

• Centella asiatica — the active ingredient in Madecassol, an approved pharmaceutical for scar treatment in Europe and Asia. Centelloids promote organised collagen deposition rather than disordered fibrosis.
• Curcuma longa — inhibits TGF-β1-driven myofibroblast differentiation, the cellular event that converts healing into hypertrophic scarring.
• Epimedium brevicornum — icariin promotes organised collagen deposition via BMP-2/Smad4 signalling, with demonstrated bone matrix organisation effects that may translate to dermal matrix quality.

5.4 Skin type universality and safety augmentation

Kongpanichakul validated LTP in Fitzpatrick III–V skin [2] — a population at elevated risk for post-inflammatory hyperpigmentation (PIH) from energy-based procedures. A combined protocol could use LTP at conservative energy settings for the thermal stimulus, followed immediately by a soothing botanical serum (chamomile bisabolol + liquorice glabridin + centella asiaticoside) to suppress the PIH cascade before it initiates.

The kask Serum Maker's skin-type-aware scoring system models this interaction: when "sensitive" skin type is selected, the system automatically boosts anti-inflammatory and soothing botanicals in the formula ranking, deprioritising potentially irritating species (ginger, cinnamon) that contain TRPV1 agonists.

5.5 Enhanced penetration through plasma-treated skin

Plasma treatment transiently disrupts the stratum corneum barrier — the primary obstacle to topical botanical bioavailability. This creates a window of enhanced permeability during which high-molecular-weight compounds that normally cannot penetrate intact skin (e.g., icariin MW 676, asiaticoside MW 959, beta-glucan polysaccharides MW >100,000) may achieve therapeutically relevant dermal concentrations.

This penetration enhancement is a double-edged sword: it could dramatically improve botanical efficacy but also increase sensitisation risk. No pharmacokinetic data exists for botanical compound absorption through plasma-treated versus untreated skin.

6. The Microbiome Dimension

The skin microbiome — approximately 1,000 species of bacteria, fungi, and viruses colonising the skin surface — plays critical roles in barrier function, immune education, and pathogen defence. None of the three plasma studies [1,2,5] measured or discussed microbiome impact. This represents a significant blind spot.

6.1 Plasma's antimicrobial effects

Ionised nitrogen generates reactive nitrogen species (RNS) with documented bactericidal activity. Even low-temperature plasma has demonstrated antimicrobial effects in wound care applications [4]. The question is whether PSR/LTP sterilises the treatment zone, selectively reduces certain populations, or leaves the microbiome largely intact beneath the desiccated epidermal dressing.

6.2 Botanical microbiome modulation

The Serum Maker explicitly models microbiome impact through six interaction pathways:

• Prebiotic support — beta-glucan polysaccharides (from Ganoderma lucidum, Grifola frondosa, Trametes versicolor, Inonotus obliquus) act as substrates for beneficial Staphylococcus epidermidis recolonisation
• Selective antimicrobial activity — thymoquinone (Nigella sativa), EGCG (Camellia sinensis), and eugenol (Ocimum tenuiflorum) demonstrate preferential activity against pathogenic Cutibacterium acnes and Staphylococcus aureus while preserving commensal populations at typical topical concentrations
• AMP induction — immunomodulatory botanicals support keratinocyte production of antimicrobial peptides (cathelicidin LL-37, human β-defensins) that maintain microbial homeostasis
• Anti-inflammatory dysbiosis prevention — NF-κB-driven inflammation shifts the skin microbiome toward pathogenic states; botanical anti-inflammatories (curcumin, boswellic acids, bisabolol) reduce these dysbiosis-promoting signals

7. Research Gaps

The following eight gaps represent the most immediate opportunities for translational investigation. Each is classified by feasibility (study complexity) and potential impact.

8. Proposed Investigation Framework

Based on the synergy analysis and gap identification, we propose a phased investigation framework:

Phase 0 — Ex vivo permeation studies

Franz cell diffusion studies using porcine or human ex vivo skin treated with LTP at 2 J and 4 J versus untreated controls. Receptor fluid analysed by HPLC for: asiaticoside, curcumin, icariin, EGCG, glabridin, thymoquinone. Establishes the permeation enhancement factor for each compound class at each energy level. Duration: 3 months.

Phase 1 — Microbiome characterisation

Prospective observational study (n=20). 16S rRNA sequencing of facial skin microbiome at: baseline, 1 hour post-LTP, day 3, day 7, day 14, day 30. Split-face design: one side receives petrolatum, the other receives a standardised botanical serum (centella 2% + chamomile 1% + green tea 1%). Primary endpoint: Shannon diversity index recovery kinetics. Secondary: relative abundance of S. epidermidis versus S. aureus. Duration: 4 months.

Phase 2 — Pilot RCT: collagen quality

Split-face RCT (n=30). Both sides receive identical LTP protocol (5 weekly sessions, 4 J). One side receives petrolatum post-treatment; the other receives a standardised botanical serum applied from day 1 through week 12. Primary endpoint: collagen band thickness at 90 days (picrosirius red, polarised light microscopy). Secondary endpoints: melanin index, erythema index, elasticity R2/R7, patient-rated improvement. Duration: 6 months.

Phase 3 — Multi-arm scar study

RCT (n=60) in post-acne scarring patients. Three arms: (A) PSR alone + petrolatum; (B) PSR + botanical serum (centella + curcumin + icariin); (C) botanical serum alone (no PSR). Primary endpoint: ECCA (Echelle d'Evaluation Clinique des Cicatrices d'Acné) grading at 6 months. Secondary: patient satisfaction, DLQI, histology in consenting subset. Duration: 9 months.

Phase 4 — Phase-matched botanical application

RCT (n=40) testing a three-phase botanical protocol post-LTP: Phase A (days 1–7): anti-inflammatory serum (curcumin + boswellia AKBA + chamomile bisabolol); Phase B (weeks 2–8): collagen-stimulating serum (centella + icariin + amla); Phase C (weeks 8–24): depigmenting serum (glabridin + amla + green tea EGCG). Compared against single-formula application throughout. Duration: 12 months.

9. Related Areas of Interest

9.1 Cold atmospheric plasma (CAP) and wound healing

A rapidly growing field in surgical and chronic wound management where plasma is used at even lower temperatures than LTP. CAP generates reactive oxygen and nitrogen species (RONS) that directly modulate cell signalling. Botanical antioxidants could buffer excessive RONS while preserving the beneficial signalling threshold — a dose-dependent interaction that requires careful characterisation.

9.2 Plasma-mediated transdermal delivery

Plasma microporation is being studied as a drug delivery enhancement technique independent of rejuvenation. This directly connects to the Serum Maker's penetration model: plasma could be used not just for rejuvenation but as a delivery vehicle for botanical actives that normally cannot penetrate the stratum corneum — particularly glycosylated flavonoids (icariin MW 676, asiaticoside MW 959) and polysaccharides (beta-glucans MW >100,000).

9.3 Senolytic botanicals and plasma

9.4 Photobiomodulation as a third modality

Low-level light therapy (red/NIR, 630–850 nm) also stimulates fibroblast collagen production via cytochrome c oxidase activation. A three-modality protocol — plasma (thermal stimulus) → botanical serum (molecular support) → photobiomodulation (mitochondrial activation) — could provide complementary stimulation across three distinct mechanistic pathways in a single treatment session.

9.5 Personalised formulation via skin microbiome profiling

The Serum Maker currently uses heuristic microbiome impact predictions based on compound class and pharmacological action. Combining this with actual 16S rRNA sequencing of a patient's skin microbiome pre- and post-plasma could enable truly personalised botanical serum formulation — selecting prebiotics and selective antimicrobials based on the individual's microbial ecology rather than population averages. This represents the convergence of precision dermatology, microbiome science, and computational phytopharmacology.

9.6 Regulatory pathway considerations

Botanical serums applied to plasma-treated skin occupy an ambiguous regulatory space. If the serum is classified as a cosmetic, the enhanced penetration through disrupted stratum corneum may push it toward drug classification in some jurisdictions. If the plasma device is used specifically to enhance botanical delivery (rather than for rejuvenation per se), the combination may require device-drug combination product regulatory review. Early engagement with regulatory frameworks (FDA 21 CFR, EU MDR, TGA) is advisable.

10. Limitations

• No direct experimental data. This paper is a synergy analysis and gap map, not a report of original experimental results. All proposed synergies are based on mechanistic reasoning from independent evidence bases.
• Botanical evidence heterogeneity. The evidence levels for individual botanicals range from Cochrane-reviewed (andrographis for URI) to preclinical only (ashitaba DMC for senolysis). Extrapolation from systemic to topical application introduces additional uncertainty.
• Plasma device variability. The three source studies used different devices (Portrait PSR, BIOPlasma jet, Plasma Pen Maglev), different energy protocols, and different treatment schedules. Direct comparison across studies is limited.
• Serum Maker heuristics. The skin property radar, penetration profile, and microbiome impact predictions in the kask Serum Maker are computational heuristics based on compound class properties, not validated pharmacokinetic models. They should be treated as hypothesis-generating tools, not clinical predictions.
• Small source study populations. Bogle (n=8), Almohammad (n=20), and Kongpanichakul (n=40) are small studies. The proposed investigation framework addresses this with larger sample sizes, but the synergy hypotheses rest on limited primary data.
• Publication bias. Plasma skin regeneration literature skews positive. Negative or null results from unpublished industry-sponsored trials may exist.

11. References